Omega-3, Autism Spectrum Disorder (ASD)

Omega-3 Fatty Acids and Autism Spectrum Disorder (ASD) - A Double-blind Randomized Controlled Trial of Omega-3 Fatty Acids in Youth With ASD

This is a 12 week study to investigate the effects of omega-3 polyunsaturated fatty acids (PUFAs) in youth with autism spectrum disorder (ASD).

This is a 12 week study to investigate the effects of omega-3 PUFAs in children (6-17 years-old) with ASD.

The primary outcome will be the clinical symptoms rated by the Aberrant Behavior Checklist (ABC). The secondary outcomes will be inflammatory biomarkers, cognitive function and physiological markers such as heart-rate variability (HRV).

Inclusion Criteria:

• diagnosis of DSM5 ASD made by child and adolescent psychiatrist
• age 6-17 years-old at the time of enrolment
• no pharmacotherapy or non-pharmacotherapy adjustment within the past 4 weeks,
• Signed informed consent.

Exclusion Criteria:

• comorbid other psychiatric disorders, including schizophrenia or affective mood disorder (Bipolar and Major Depressive Disorder), or substance use disorder
• comorbid physical disorders, such as thyroid dysfunction, cerebral palsy, coagulation disorders
• currently using omega-3 supplements or probiotics
• allergy to omega-3.